Your Good Partner in Biology Research

Human Glucose dependent insulin releasing polypeptide,GIP ELISA Kit

  • 中文名称:
    人葡萄糖依赖性胰岛素释放多肽(GIP)酶联免疫试剂盒
  • 货号:
    CSB-E08484h
  • 规格:
    96T/48T
  • 价格:
    ¥3200/¥2500
  • 其他:

产品详情

  • 产品描述:
    CUSABIO人葡萄糖依赖性胰岛素释放多肽(GIP)酶联免疫试剂盒(货号CSB-E08484h),基于双抗体夹心法定量检测血清、血浆及组织匀浆样本中的GIP浓度。GIP是由肠道K细胞分泌的肠促胰岛素,通过促进餐后胰岛素释放参与血糖调节,其表达水平与2型糖尿病、肥胖等代谢性疾病密切相关,是研究能量代谢与内分泌调控的重要生物标志物。该试剂盒检测范围为12.5-200 ng/ml,通过预包被特异性抗体实现高灵敏度检测,适用于基础科研中探索GIP在代谢调控中的作用机制、评估疾病模型动物体内激素水平变化,或用于体外研究药物、营养素等干预对GIP分泌的影响。实验操作兼容常规酶标仪分析,支持批量样本检测,为开展胃肠激素相关分子机制研究及代谢疾病治疗策略开发提供可靠工具。本产品严格限定于科学研究用途。
  • 别名:
    Gastric Inhibitory Peptide ELISA Kit; Gastric inhibitory polypeptide ELISA Kit; Gastric inhibitory polypeptide precursor ELISA Kit; GIP ELISA Kit; GIP_HUMAN ELISA Kit; Glucose dependent insulinotropic polypeptide ELISA Kit; Glucose-dependent insulinotropic polypeptide ELISA Kit; Incretin hormone ELISA Kit
  • 缩写:
  • Uniprot No.:
  • 种属:
    Homo sapiens (Human)
  • 样本类型:
    serum, plasma, tissue homogenates
  • 检测范围:
    12.5 ng/ml-200 ng/ml.
  • 灵敏度:
    2.5 ng/ml.
  • 反应时间:
    1-5h
  • 样本体积:
    50-100ul
  • 检测波长:
    450 nm
  • 研究领域:
    Signal Transduction
  • 测定原理:
    quantitative
  • 测定方法:
    Sandwich
  • 精密度:


  • 线性度:

  • 回收率:

  • 标准曲线:

  • 数据处理:
  • 货期:
    3-5 working days

引用文献

产品评价

相关问答

 常见问题解答
Q:

我有一个关于CSB-E08484h、CSB-E08119h和CSB-E09207h产品的技术问题。这些试剂盒的酶标板是怎样的?(标准品、对照和样品分别占多少孔位?)

A:
这三种产品都是夹心式ELISA试剂盒(双抗)。对于96孔夹心式ELISA试剂盒(双抗),我们建议您对标样进行重复测试。通常可以测试80个样品。如果对样品进行重复测试,就可以测试40个样品。您可以根据样品数量决定需要多少个试剂盒。如果您进行预实验,一个试剂盒可以检测的样品数量会减少。

靶点详情

  • 功能:
    Potent stimulator of insulin secretion and relatively poor inhibitor of gastric acid secretion.
  • 基因功能参考文献:
    1. The genetic variability of GIP gene is associated with coronary artery disease and it may play a role in the premature coronary artery disease in the Chinese Han population with type 2 diabetes. PMID: 29765988
    2. The ability of a truncated form of GIP, GIP(3-30)NH2, to antagonize the physiological actions of GIP in glucose metabolism, subcutaneous abdominal adipose tissue blood flow, and lipid metabolism in humans. PMID: 28667118
    3. GIP and PP plasma concentrations are lower in pancreatic cancer irrespective of the degree of glucose intolerance as compared to Type 2 diabetic patients and healthy controls. PMID: 28027898
    4. Evening postprandial insulin and GIP responses and insulin resistance declined by over 30% after three meals that limited daily carbohydrate intake to 30% compared to no such changes after three 60%-carbohydrate meals, an effect that was independent of pre-meal exercise. PMID: 27798656
    5. the stimulatory effect of IGF-1 on GIP promoter support the hypothesis of a functional growth hormone-igf-1-GIP axis PMID: 28179449
    6. decreased maternal 25OHD may be associated with decreased cord 25OHD and increased cord GLP-1 and GIP levels, which may be involved with the transfer of maternal glucose to the fetus PMID: 26650343
    7. Excess androgen activity might be a factor contributing to alter secretion of incretins in lean polycystic ovary syndrome (PCOS) women. However it could not be ruled out that it is also possible that increased GIP levels might induce hyperandrogenemia in PCOS. PMID: 26895276
    8. Our results might indicate an altered DPP4-incretin system and altered immunoregulation including a potentially dysfunctional GLP1(9)(-)(36) signaling in T1DM. PMID: 26434625
    9. Fasting GIP concentrations are higher in individuals with a history of cardiovascular disease (myocardial infarction, stroke) when compared with control subjects. PMID: 26395740
    10. Data suggest that high levels of blood glucose or AGEs (advanced glycation end products), as seen in hyperglycemia, reduce secretion of insulin by pancreatic beta cells via antagonism of GIP (gastric inhibitory polypeptide)/GIP receptor signaling. PMID: 26221611
    11. Data confirm that postprandial plasma levels of glucose-dependent insulinotropic polypeptide (GIP) and insulin (INS) are responsive to glycemic index of foods consumed; glycemic index of breakfast cereals regulate plasma postprandial GIP and INS. PMID: 25852025
    12. irisin and GIP might contribute to the development of polycystic ovary syndrome and may also represent novel polycystic ovary syndrome biomarkers PMID: 25029417
    13. Data suggest that postprandial blood levels of both GIP and insulin can be regulated by diet; here, inclusion of nopal/Opuntia/cactus (a functional food in traditional Mexican medicine) in breakfast reduces postprandial levels of GIP and insulin. PMID: 25132122
    14. phosphatidylinositol 3-kinase gamma has a role in insulin secretion induced by glucose-dependent insulinotropic polypeptide PMID: 25288806
    15. These novel results support the notion that the GIP-GIPR axis plays a role in the etiology of central obesity in humans PMID: 25324507
    16. Data from studies in healthy Japanese men suggest that plasma GIP levels in postprandial period are dose dependently increased by fat content of meals of ordinary size, despite the amount of additional fat being relatively small. PMID: 24507870
    17. Patients with idiopathic gastroparesis exhibit abnormal GIP levels. PMID: 23663508
    18. Beta cell connectedness is an inherent property of human islets that is likely to influence incretin-potentiated insulin secretion. PMID: 24018562
    19. Data suggest that postprandial plasma levels of glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP1) are increased after consumption of buckwheat crackers versus rice crackers in healthy and type 2 diabetic subjects. PMID: 23485142
    20. GIP induces an inflammatory and prolipolytic response via the PKA -NF-kappaB-IL-1 pathway and impairs insulin sensitivity of glucose uptake in human adipocytes. PMID: 23092914
    21. results indicate postprandial GIP secretion in early-phase after test meal in Japanese patients with type 2 diabetes was positively correlated with BMI, but not those with type 1 diabetes PMID: 22301939
    22. Hyperinsulinemia subjects with metabolic syndrome showed increased GIP secretion that could be responsible for the delayed glucagon suppression. PMID: 22391044
    23. Data suggest that reduced insulinotropic effect of GIP or GLP-1 (as in type 2 diabetes) can be induced in healthy subjects; this indicates that reduced incretin stimulation of insulin secretion results from insulin resistance/glucose intolerance. PMID: 22319034
    24. GIP reduces free fatty acid release from adipose tissue by inhibition of lipolysis or by increased reesterification. PMID: 22179810
    25. may have a pro-obesogenic action [review] PMID: 21815989
    26. Studies identified some potentially important additional C-terminal interactions of GIP with its N-terminal extracellular receptor domain. PMID: 21539943
    27. We report that the human GIP locus was differentially selected in East Asians about 8100 years ago based on the analysis of a nonsynonymous SNP (rs2291725). PMID: 20978139
    28. GLP-2, but not GIP, was found to stimulate the release of glucagon in patients with T1DM, suggesting a role for GLP-2 in the postprandial hyperglucagonaemia characterising individuals with T1DM PMID: 20580750
    29. These results suggest that Tyr/His(1) and Ile/Thr(7) of GIP/GLP-1 peptides confer differential ligand selectivity toward GIPR and GLP1R. PMID: 20799012
    30. We demonstrate for the first time that changes in insulin secretion after lifestyle intervention may be mediated via alterations in GIP secretion from intestinal K-cells PMID: 20200305
    31. No statistically significant association was observed between any of the single nucleotide polymorphisms of GIP analysed and type 2 diabetes in our population. PMID: 20673334
    32. GIP is expressed in and secreted from pancreatic islets and promotes islet glucose competence and also could support islet development and/or survival. PMID: 20138041
    33. a binding mode of GIP to GIPR in which the N-terminal moiety of GIP was sited within transmembrane helices (TMH) 2, 3, 5, and 6 with biologically crucial Tyr1 interacting with Gln224 (TMH3), Arg300 (TMH5), and Phe357 (TMH6). PMID: 20061446
    34. Substitution of Glu(3) in GIP with proline produces a novel dipeptidylpeptidase IV-resistant GIP antagonist which inhibits GIP-induced cAMP generation and insulin secretion with high sensitivity and specificity in vitro. PMID: 11820780
    35. activates the Raf-Mek1/2-ERK1/2 module via a cyclic AMP/cAMP-dependent protein kinase/Rap1-mediated pathway PMID: 12138104
    36. Mutation in promoter region of gip receptor gene are unlikely to underlie GIP-dependent Cushing syndrome. PMID: 12530694
    37. Elevated plasma GIP levels are correlated with hyperinsulinemia in the impaired glucose-tolerant state, whereas type 2 diabetes is associated with a failure to secrete adequate amounts of GIP. PMID: 15220248
    38. bombesin and nutrients additively stimulate GIP release from GIP/Ins cells. PMID: 15383372
    39. Results describe the solution structure of GIP(1-30)amide, the major biologically active fragment of glucose-dependent insulinotropic polypeptide. PMID: 15522230
    40. GIP augments glucose-stimulated insulin secretion and acts as an endogenous inhibitor of gastric acid secretion--REVIEW PMID: 15533777
    41. GIP stimulates insulin secretion by potentiating events underlying membrane depolarization and exerting direct effects on exocytosis. PMID: 15955806
    42. The relationship between insulin resistance and the insulin secretion to GIP suggests that beta cell secretory function in response to different stimuli increases adaptively when insulin sensitivity is diminished, as in gestational diabetes. PMID: 16010522
    43. GIP is rapidly degraded into inactive metabolites by the enzyme dipeptidyl-peptidase-IV. (review) PMID: 16142014
    44. protein kinase B, LKB1, and AMP-activated protein kinase have roles in activation of lipoprotein lipase by glucose-dependent insulinotropic polypeptide in adipocytes PMID: 17244606
    45. study identified a splice site mutation of the Glucose-dependent insulinotropic polypeptide (GIP) gene which results in a truncated protein and provides evidence for association of GIP receptor genotype with cardiovascular disease PMID: 17624916
    46. physiologic role for GIP in lipid homeostasis and possibly in the pathogenesis of obesity. PMID: 18054552
    47. concomitant expression of Pax6 and Pdx1 is important for glucose-dependent insulinotropic polypeptide expression PMID: 18593849
    48. GIP secretion is blunted after the biliopancreatic diversion only in diabetic patients, suggesting a role in insulin resistance and diabetes. PMID: 19229515
    49. GIP may mediate the attenuated glucose-stimulated insulin response after exercise/diet interventions PMID: 19351807
    50. Inhibition of apoptosis by GIP is mediated via a key pathway involving Akt-dependent inhibition of apoptosis signal-regulating kinase 1, which subsequently prevents the pro-apoptotic actions of p38 MAPK and JNK. PMID: 19748889

    显示更多

    收起更多

  • 亚细胞定位:
    Secreted.
  • 蛋白家族:
    Glucagon family
  • 数据库链接:

    HGNC: 4270

    OMIM: 137240

    KEGG: hsa:2695

    STRING: 9606.ENSP00000350005

    UniGene: Hs.1454